Consistency of extended-release niacin/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups

American Journal of Cardiovascular Drugs

Volumn 12, Issue 3, 2012, Pages 197-206

  Bays, Harold E ^a   Shah, Arvind ^b   Lin, Jianxin ^b   Sisk, Christine McCrary ^b   Dong, Qian ^b   MacCubbin, Darbie ^b  

^a LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Apolipoproteins; flushing; HDL cholesterol; hypercholesterolaemia; lipoprotein a; niacin

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAROPIPRANT PLUS NICOTINIC ACID; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

AGED; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; CARDIOVASCULAR DISEASES; CLINICAL TRIALS, PHASE III AS TOPIC; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPOLIPIDEMIC AGENTS; INDOLES; LIPIDS; LIPOPROTEIN(A); MALE; NIACIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84861309590     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/11631530-000000000-00000     Document Type: Article

References (25)

1. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003; 24: 1601-10 (Pubitemid 37012194)
2. Expert Panel on Detection EAToHBCIA. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97
3. Gotto Jr AM. High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease. Am Heart J 2002; 144: S33-42 (Pubitemid 36026903)
4. Shah PK, Kaul S, Nilsson J, et al. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming. Part I. Circulation 2001; 104: 2376-83 (Pubitemid 33049524)
5. Birjmohun RS, Hutten BA, Kastelein JJ, et al. Increasing HDL cholesterol with extended-release nicotinic acid: from promise to practice. Neth J Med 2004; 62: 229-34 (Pubitemid 39193956)
6. Cheng K, Wu TJ, Wu KK, et al. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci U S A 2006; 103: 6682-7
7. Illingworth DR, Stein EA, Mitchel YB, et al. Comparative effects of lovastatin and niacin in primary hypercholesterolemia: a prospective trial. Arch Intern Med 1994; 154: 1586-95 (Pubitemid 24242345)
8. Knopp RH, Ginsberg J, Albers JJ, et al. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. Metabolism 1985; 34: 642-50 (Pubitemid 15036921)
9. Mills E, Prousky J, Raskin G, et al. The safety of over-the-counter niacin: a randomized placebo-controlled trial [ISRCTN18054903]. BMC Clin Pharmacol 2003; 3: 4
10. Paolini JF, Mitchel YB, Reyes R, et al. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am J Cardiol 2008; 101: 625-30
11. Sturino CF, O'Neill G, Lachance N, et al. Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7- fluoro-5- (methylsulfonyl)-1,2,3,4-tetrahydrocy clopenta[b]indol-3-yl]-acetic acid (MK-0524). J Med Chem 2007; 50: 794-806 (Pubitemid 46332991)
12. Gleim G, Ballantyne CM, Liu N, et al. Efficacy and safety profile of coadministered ER niacin/laropiprant and simvastatin in dyslipidaemia. Br JCardiol 2009; 16: 90-7
13. Maccubbin D, Bays HE, Olsson AG, et al. Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int J Clin Pract 2008; 62: 1959-70
14. MacLean A, McKenney JM, Scott R, et al. Efficacy and safety of extendedrelease niacin/laropiprant in patients with type 2 diabetes mellitus. Br J Cardiol 2011; 18: 37-45
15. Shah S, Ceska R, Gil-Extremera B, et al. Efficacy and safety of extendedrelease niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int J Clin Pract 2010; 64: 727-38
16. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics - 2010 update: a report from the American Heart Association. Circulation 2010; 121: e46-215
17. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-34 (Pubitemid 28350165)
18. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22
19. Pekkanen J, Linn S, Heiss G, et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 1990; 322: 1700-7 (Pubitemid 20231527)
20. Bays H, Shah A,Dong Q, et al. Extended-release niacin/laropiprant lipid-altering consistency across patient subgroups. Int J Clin Pract 2011; 65: 436-45
21. Bays HE, Shah A, Lin J, et al. Efficacy and tolerability of extended-release niacin/laropiprant in dyslipidemic patients with metabolic syndrome. J Clin Lipidol 2010; 4: 515-21
22. Maccubbin D, Koren MJ, Davidson M, et al. Flushing profile of extendedrelease niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease. Am J Cardiol 2009; 104: 74-81
23. Holme I, Aastveit AH, Hammar N, et al. Inflammatory markers, lipoprotein components and risk of major cardiovascular events in 65,005 men and women in the Apolipoprotein MOrtality RISk study (AMORIS). Atherosclerosis 2010; 213: 299-305
24. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937-52 (Pubitemid 39208455)
25. Bays HE, Ballantyne C. What's the deal with niacin development: is laropiprant add-on therapy a winning strategy to beat a straight flush? Curr Opin Lipidol 2009; 20: 467-76